Incyte has grown revenue 15% a year over three years and 15% a year over five, with earnings per share compounding at 70%. Revenue growth, 3-year annual rate: +15% (Biotechnology median +17%). Revenue growth, 5-year rate: +15%, growth has picked up over the last three years. Earnings per share, 3-year rate: +70%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

INCYIncyte

Healthcare

$112.81+31% 1Y

$112.81

$81.6652 weeks$129.88

Is it growing?

Excellent

Growing: revenue growing +21% year on year, earnings up +2732% year on year, and operating margin widening (+27.5 points).

3 good

Revenue trend+21% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +15% a year.

Earnings trend+2732% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+27.5 points operating

Trailing-twelve-month operating margin, 30.5% now against 3.0% a year earlier.

All from SEC EDGAR, as of Mar 31, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is INCY growing?

Incyte has grown revenue 15% a year over three years and 15% a year over five, with earnings per share compounding at 70%.

+15%

Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +15%
Revenue growth, 5-year rate · +15% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +70%
Earnings per share, 3-year rate · revenue +15% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed